back to 2013, vol. 19, b. 1
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2013, vol. 19, book 1;
Subject Collection: Medicine
Page: 391-395
DOI: 10.5272/jimab.2013191.391
Published online: 01 April 2013

J of IMAB. 2013; 19(1):391-395;
Deyan N. DavidovCorresponding Autor
Department of Chemotherapy, Oncological center, Medical University, Pleven, Bulgaria.

Objective: Bone metastases occur in 30- 40% of patients with lung cancer. The aim of this study was to assess the efficacy and safety of Zoledronic acid, a third generation biphosphonates, in patients with non- small cell lung cancer and bone metastases. Methods: Among May 2004 and December 2008 fifty three consecutive patients with inoperable non- small cell lung cancer and bone metastases was evaluated. Zoledronic acid was administered at dose 4 mg every 3- 4 weeks as rapid intravenous infusion. All patients were treated with combination chemotherapy too.  Results: After the treatment with Zoledronic acid was observed significant reduction of serum calcium level. Serum alkaline phosphatase also decreases but not significantly. With regard of clinical efficacy 36 of patients stabilized or reduced their needs for analgesic treatment. No grade 4 side effects were recorded. Conclusion: Zoledronic acid as rapid intravenous infusion is safe and convenient in the treatment of patients with non- small cell lung cancer and bone metastases.

Key words: Zoledronic acid, Non- small cell lung cancer, Bone metastases.

- Download FULL TEXT /PDF 610 KB/
Please cite this article as:
Davidov DN. Our Experience with Zoledronic Acid in the Treatment of Patients with Non- Small Cell Lung Cancer and Bone Metastases. J of IMAB. 2013; 19(1):391-395. DOI: 10.5272/jimab.2013191.391.

Correspondence to: Dr. Deyan Nikolov Davidov, Department of Chemotherapy, Oncological Center, Medical University Pleven; 1, "St. Kliment Ohridsky" Str., 5000 Pleven, Bulgaria.

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA CancerJ Clin. 2007 Jan-Feb;57(1):43- 66. [PubMed]
2. Cersosimo RJ. Lung cancer: a review. Am J Health Syst Pharm. 2002 Apr 1;59(7):611- 642. [PubMed]
3. Stinchcombe TE, Lee CB, Socinski MA. Current approaches to advanced- stage non- small cell lung cancer: first-line therapy in patients with a good functional status. Clin Lung Cancer. 2006 May;7 (suppl 4):S111- S117. [PubMed]
4. Zawisza D, Pepe C, Mittmann N,  Feld R, Shepherd F, Leighl N. The potential for lost productivity in lung cancer patients. J Clin Oncol. 2006; 24 (suppl):323s. Abstract 6093.
5. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001 Jun;27(3):165–176. [PubMed] [CrossRef]
6. Coleman RE. Skeletal complications of malignancy. Cancer. 1997 Oct 15;80(8 suppl):1588-94. [PubMed] [CrossRef]
7. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HG, et al.  Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001 Jan 15;19(2):558- 567. [PubMed]
8. Berenson JR, Rosen LS, Howel A, Porter L, Coleman RE, Morley W, et al. Zoledronic acid reduces skeletal- related events in patients with osteolytic metastases: A double- blind, randomized dose- response study. Cancer. 2001 Apr 1;91(7):1191- 1200. [PubMed] [CrossRef]
9. Rosen LS, Gordon D, Tchekmedyan S, Yanaqihara R, Hirsh W, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double- blind, randomized trial-the zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol, 2003; 21: 3150- 3157.
10. World Health Organization: Cancer pain relief. WHO publication center, Albany, New York, 1986.
11. Cameron D. Patient management issues in metastatic bone disease. Semin Oncol. 2004 Oct;31(5 Suppl 10):79- 82. [PubMed] [CrossRef]
12. Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist. 2005 Jan;10(1):52-62. [PubMed] [CrossRef]
13. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by biphosphonates. Leukemia. 1998 Feb;12(2):220- 229. [PubMed]
14. Lee MV, Fong EM, Singer FR, Guenette RS. Biphosphonates treatment inhibits the growth of prostate cancer cells. Cancer Res. 2001 Mar 15;61(6):2602- 2608. [PubMed]
15. Syrigos KN, Michalaki V, Mitromaras A, Pliarchopoulou F, Katirzoglou N, Antonaki E, et al. Safety and efficacy of the new biphosphonate ibandronate in the management of bone metastasis following rapid infusion. In vivo, 2002 Sep-Oct;16(5):361-364. [PubMed]

Accepted for publication: 23 October 2012
Published online: 01 April 2013

back to Online Journal